1. ISPOR POLAND CHAPTER Polish Society of Pharmacoeconomics (PTFe )

2. International examples Acceptedmultidisciplinary methodology methodology PharmacoeconomicsinPoland Optimizing pharmacotherapy through rational drugs management

3. Pharmacoeconomics in Poland Regulations Methodology/Standardization Polish terminology Existing resources Educational opportunities

4. REGULATIONS 1.Act on Health Services Financed from Public Sources a)Necessity of justyfying proposed price b)Evidence on clinical efficiacy, cost- effectiveness and budget impact analysis (for innovative drugs) 2.Act on Prices 3.Regulations concerning Health Technology Assessment Agency a)Economic evaluation including cost analysis b)Influence on financing from public sources 4.Requirements concerning Treatment Programmes financed by the National Health Fund a)Defining cost-endpoint relationship

5. METHODOLOGY/TERMINOLOGY 1.Polish Guidlines for conducting pharmacoeconomic evaluations (2000) approved by ISPOR Polish Chapter 2.The Polish Dictionary of Pharmacoeconomics 1st and 2nd editions 3.Textbooks and manuals

6. Limit prices for reimbursed drugs The same active substance, different market price. Generic limit price Therapeutic limit price Different active substances, the same effect, different market price. REIMBURSEMENT SYSTEM Fixed charge 70%50% Basic and supplementary list

7. ISPOR POLAND CHAPTER in 2005-2006 Organizing the 3rd Scientific Conference of the Polish Society of Pharmacoeconomics: („Reimbursement systems in EU countries; discussion about activities of the Society members in working groups of ISPOR Organizing the 3rd Scientific Conference of the Polish Society of Pharmacoeconomics: („Reimbursement systems in EU countries; discussion about activities of the Society members in working groups of ISPOR 1. Working on the 4th Scientific Conference of the Polish Society of Pharmacoeconomics (focused on : pharmacoeconomics and economic evaluation of heath care programs; prof. Paul Kind as a main speaker: “Patient reported outcomes and quality of life”; inviting Czech and Russian ISPOR Chapters Presidents 2. Creating Student Section within the Polish Society of Pharmacoeconomics with 25 members in order to promote interest and awareness about pharmacoeconomics, health outcome research to various disciplines across members of health-related organizations and universities in Poland 3. Educational support of Student Section by PTFE – lectures –„Pharmacoeconomics in Polish perspective” –„Health and economics” prof. Tomasz Hermanowski

8. ISPOR POLAND CHAPTER in 2005-2006 1. Cooperation with medical societies in educational area – lectures on pharmacoeconomics for relevant scientific and medical societies 2. Discussion with representatives of the Ministry of Health about principles of pricing and reimbursement system in Poland in relation to pharmacoeconomics 3. Discussion with the Association of Pharmaceutical Industry in Poland on the Code of Marketing Ethics. Stating an objection against the use of pharmacoeconomic studies as a marketing tool. Stating an objection against the use of pharmacoeconomic studies as a marketing tool. 4. Representing the Polish Society of Pharmacoeconomics on the following conferences: the 7th Congress of European Association for Clinical Pharmacology and Thearpautics” the 7th Congress of European Association for Clinical Pharmacology and Thearpautics” Lectures about the role of pharmacoeconomics in drug policy, Lectures about the role of pharmacoeconomics in drug policy, Conference of Quality Management Center, Cracow, Conference of Quality Management Center, Cracow, Workshop for hospitals’ directors and pharmacists: ’’Pharmacoeconomics in atreatment process”, Oct. 2006 Workshop for hospitals’ directors and pharmacists: ’’Pharmacoeconomics in atreatment process”, Oct. 2006 participation in experts panel „How clinical trials for new drugs should be financing?”, Oct. 2006 participation in experts panel „How clinical trials for new drugs should be financing?”, Oct. 2006